These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16759031)

  • 1. The growing child with thalassaemia.
    Skordis N
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):467-9. PubMed ID: 16759031
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth and management of short stature in thalassaemia major.
    Theodoridis C; Ladis V; Papatheodorou A; Berdousi H; Palamidou F; Evagelopoulou C; Athanassaki K; Konstantoura O; Kattamis C
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():835-44. PubMed ID: 10091154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celiac disease in a patient with beta-thalassemia major.
    Acquaviva A; Municchi G; Marconcini S; D'Ambrosio A; Morgese G
    J Pediatr Gastroenterol Nutr; 2003 Apr; 36(4):489-91. PubMed ID: 12658042
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V; Roos M; Gasser T; Fortini M; Raiola G; Galati MC;
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):471-80. PubMed ID: 16759032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
    Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
    Calleja EM; Shen JY; Lesser M; Grady RW; New MI; Giardina PJ
    Ann N Y Acad Sci; 1998 Jun; 850():469-70. PubMed ID: 9668587
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and complications of thalassemia major in Guangxi, Southern China.
    Yin XL; Wu ZK; He YY; Zhou TH; Zhou YL; Zhang XH
    Pediatr Blood Cancer; 2011 Dec; 57(7):1174-8. PubMed ID: 21394896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract]   [Full Text] [Related]  

  • 11. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong.
    Kwan EY; Lee AC; Li AM; Tam SC; Chan CF; Lau YL; Low LC
    J Paediatr Child Health; 1995 Apr; 31(2):83-7. PubMed ID: 7794630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth, puberty and endocrine function in beta-thalassaemia major.
    Low LC
    J Pediatr Endocrinol Metab; 1997; 10(2):175-84. PubMed ID: 9364350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extreme cardiac iron loading in transfusion-dependent thalassaemia major: cardiac T2* and T1 mapping guiding treatment.
    Brown RA; Moon JC; Telfer PT; Khanji MY
    Eur Heart J; 2019 Nov; 40(43):3578. PubMed ID: 30879023
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcome of thalassemia treated with conventional therapy.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; Boffa C; DeSanctis V; DiPalma A; DiGregorio L; Melevendi C; Piga A; Sabato V
    Bone Marrow Transplant; 1993; 12 Suppl 1():2-4. PubMed ID: 8374554
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H; Shahriari M; Sadjadian N
    East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose tolerance and beta-cell secretion in patients with thalassaemia major.
    Mangiagli A; Italia S; Campisi S
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():985-6. PubMed ID: 10091179
    [No Abstract]   [Full Text] [Related]  

  • 18. A decisional algorithm to start iron chelation in patients with beta thalassemia.
    Danjou F; Cabantchik ZI; Origa R; Moi P; Marcias M; Barella S; Defraia E; Dessì C; Foschini ML; Giagu N; Leoni GB; Morittu M; Galanello R
    Haematologica; 2014 Mar; 99(3):e38-40. PubMed ID: 24598857
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of puberty for optimal auxological results in beta-thalassaemia major.
    Caruso-Nicoletti M; De Sanctis V; Cavallo L; Raiola G; Ruggiero L; Skordis N; Wonke B;
    J Pediatr Endocrinol Metab; 2001 Jul; 14 Suppl 2():939-44. PubMed ID: 11529399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth in children after bone marrow transplantation for thalassemia.
    Gaziev J; Galimberti M; Giardini C; Baronciani D; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():100-1. PubMed ID: 8374543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.